Most Read Articles
Stephen Padilla, Yesterday
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
01 Aug 2020
Ensituximab, a chimeric monoclonal antibody targeting a variant of MUC5AC, shows modest clinical activity with good safety profile in patients with refractory colorectal cancer, according to data from a phase II study.
Roshini Claire Anthony, 30 Jul 2020

Frailty may indicate an increased risk of death from COVID-19, results of the COPE* study showed.

Low retransplantation rate tied to increased mortality in recurring autoimmune hepatitis

30 Jul 2020

The low rate of retransplantation in patients with recurring autoimmune hepatitis (AIH) is partly to blame for the greater post-transplant mortality in this population compared with other autoimmune liver disease, suggests a recent study.

Autoimmune liver diseases, such as primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and AIH, generally have favourable post-transplant outcomes, with prior studies showing that the risk of disease recurrence is similar in AIH and PSC. In addition, the latter is known to require more retransplantation than PBC.

The investigators compared post-transplant graft survival and the need for retransplant in AIH compared with other autoimmune liver diseases using Cox regression, as well as competing risk analyses using the United Network for Organ Sharing database.

After controlling for potential confounders, AIH was found to significantly correlate with lower graft survival than PBC (hazard ratio [HR], 0.86, 95 percent confidence interval [CI], 0.77–0.96) and PSC (HR, 0.89, 95 percent CI, 0.8–0.99), which was primarily driven by post-transplant death.

Competing risk analysis also revealed a higher risk of death with AIH compared with PBC (subdistribution HR, 0.79, 95 percent CI, 0.7–0.89) and PSC (subdistribution HR, 0.72, 95 percent CI, 0.64–0.82). In addition, AIH was associated with a lower risk of retransplant than PSC (subdistribution HR, 1.48, 95 percent CI, 1.19–1.8).

A recent population-based prospective study found a significantly higher incidence of AIH from 2014–2016 than 2008–2010, while incidences of PBC and PSC remained the same over the same period. [Clin Gastroenterol Hepatol 2020;doi:10.1016/j.cgh.2020.05.061]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, Yesterday
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
01 Aug 2020
Ensituximab, a chimeric monoclonal antibody targeting a variant of MUC5AC, shows modest clinical activity with good safety profile in patients with refractory colorectal cancer, according to data from a phase II study.
Roshini Claire Anthony, 30 Jul 2020

Frailty may indicate an increased risk of death from COVID-19, results of the COPE* study showed.